Advertisement
U.S. markets close in 20 minutes

Novus Acquisition & Development Corp. (NDEV)

Other OTC - Other OTC Delayed Price. Currency in USD
0.02230.0000 (0.00%)
As of 01:24PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0223
Open0.0223
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0203 - 0.0223
52 Week Range0.0112 - 0.0350
Volume12,500
Avg. Volume16,781
Market Cap2.399M
Beta (5Y Monthly)-0.38
PE Ratio (TTM)22.25
EPS (TTM)0.0010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NDEV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NOVUS ACQUISITION & DEVELOPMENT
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • PR Newswire

    Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans

    Branded Legacy, Inc (OTC.PK: BLEG), an emerging biotechnology company, is excited to announce a strategic partnership with Novus Acquisition & Development Corp (OTC.PK: NDEV), a national supplemental health insurance carrier that is a pioneer in offering cannabis-embedded health plans for both recreational and medical use. This collaboration marks a significant milestone in Branded Legacy's mission to revolutionize the biotechnology landscape while creating a profound impact on the healthcare in

  • ACCESSWIRE

    Novus Releases Its First Quarter Financial Statements For 2023

    Novus Acquisition and Development, Corp. (OTC Markets:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, Inc. Operates as a national supplemental health insurance carrier and, the nation's first health carrier offering cannabis that is included in health plans for recreational and medicinal users.